Phase I
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
If the road to success is paved with failures, then the road to an effective, approved drug is paved with flops. Merck and Enanta are adding some painful pavers to their own roads this week.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
After 32 years, gene therapy pioneer Guangping Gao, Ph.D., is finally seeing the fruits of the doctoral thesis research he started in 1989.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
The investigational drug directs a patient’s own IL-2 toward immune activation while simultaneously preventing IL-2’s immune suppression activities.
It was another busy week for clinical trial news. Here’s a look.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Selecta Biosciences, Inc. (NASDAQ: SELB), today announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTORTM platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies.
PRESS RELEASES